Fibrotic Pulmonary Sarcoidosis.
Fibrosis
Granuloma
Morbidity
Mortality
Progression
Journal
Clinics in chest medicine
ISSN: 1557-8216
Titre abrégé: Clin Chest Med
Pays: United States
ID NLM: 7907612
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
medline:
21
1
2024
pubmed:
21
1
2024
entrez:
20
1
2024
Statut:
ppublish
Résumé
Fibrotic pulmonary sarcoidosis (fPS) affects about 20% of patients. fPS carries a significant morbidity and mortality. However, its prognosis is highly variable, depending mainly on fibrosis extent, functional impairment severity, and the development of pulmonary hypertension. Moreover, fPS outcomes are also influenced by several other complications, including acute exacerbations, and infections. fPS natural history is unknown, in particular regarding the risk of progressive self-sustaining fibrosis. The management of fPS is challenging, including anti-inflammatory treatment if granulomatous activity persists, rehabilitation, and in highly selected patients antifibrotic treatment and lung transplantation.
Identifiants
pubmed: 38245367
pii: S0272-5231(23)00080-1
doi: 10.1016/j.ccm.2023.08.011
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
199-212Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.